Aptevo Therapeutics

Yahoo Finance • 10 days ago

Discover the most active stocks in Tuesday's session.

Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active stocks in today's session. [mostactive] TODAY'S MOST ACTIVE STOCKS TICKER CHANGE COMMENT ADAP [https://www.chartmill.com/... Full story

Yahoo Finance • 10 days ago

Let's uncover which stocks are experiencing notable gaps during today's session.

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE... Full story

Yahoo Finance • 2 months ago

Aptevo Therapeutics files to sell 8.25M shares of common stock for holders

* Aptevo Therapeutics (NASDAQ:APVO [https://seekingalpha.com/symbol/APVO]) filed to sell 8.25M shares of common stock for holders. * This prospectus is not an offer to sell. * Filing [https://seekingalpha.com/filing/10221556] MORE O... Full story

Yahoo Finance • 3 months ago

Aptevo regains Nasdaq compliance following $15.9 million equity raise

Aptevo Therapeutics Inc . (NASDAQ:APVO) announced Tuesday that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of $2.5 million in stockholders’ equity. The company rece... Full story

Yahoo Finance • 3 months ago

Aptevo Therapeutics announces $8M at-the-market equity offering with warrants; shares more than double

* Aptevo Therapeutics (NASDAQ:APVO [https://seekingalpha.com/symbol/APVO]) has entered into securities purchase agreements to raise ~$8M through a registered direct offering. * The deal includes 2.47M shares of common stock or pre-fund... Full story

Yahoo Finance • 2 years ago

Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update

Company Achieves Multiple Clinical and Preclinical Milestones and Raises $9.7 Million in Non-Dilutive Funding, Eliminates Balance Sheet Debt Introduces Novel Compound APVO711, Dual Mechanism of Action Includes Both Checkpoint Inhibitor an... Full story

Yahoo Finance • 3 years ago

Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia

Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Patients Treated to Date Cohort 3 Monotherapy Patient Achieved Bone Marrow Complete Remission Company Also Reports Myelodysplastic Syndrome Patient Enroll... Full story